Corrigendum
The authors wish to make the following corrections to their article: Mannaioni G, Lugoboni F. Precautions in the management of opioid agonist therapy: from target population characteristics to new formulations and post-marketing monitoring – a focus on the Italian system. Drugs Context. 2023;12:2023-2-6. https://doi.org/10.7573/dic.2023-2-6
Review
This articles aims is to provide useful information and insights for the management of opioid agonist therapy by providing an overview that ranges from the characteristics of opioid use disorder patients to the macroscopic phenomena of social-health significance on a national scale, with a particular focus on the Italian territory.
Original Research
Prucalopride is a selective serotonin type 4 (5-HT4) receptor agonist indicated for treatment of chronic idiopathic constipation in adults. 5-HT4 receptors are present in the central nervous system; therefore, this article discusses non-clinical and clinical assessments evaluating the tissue distribution and abuse potential of prucalopride.
